Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Compugen Ltd. (NASDAQ:CGEN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the five analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month target price […]
Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode.
Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript November 7, 2023 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.11 EPS, expectations were $-0.09. Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Third Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. As […]
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery,...
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among brokers […]